ILMN 102.12 ▲ 2.84% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Illumina Inc.

    NASDAQ: ILMN · Real-Time Price · USD
    102.12
    2.82 (2.84%)
    At close: Oct 03, 2025, 3:59 PM
    102.02
    -0.10%
    After-hours: Oct 03, 2025, 07:23 PM EDT
    2.84%
    Bid 100.25
    Market Cap 15.7B
    Revenue (ttm) 4.28B
    Net Income (ttm) 1.26B
    EPS (ttm) 7.9
    PE Ratio (ttm) 12.93
    Forward PE 20.6
    Analyst Hold
    Dividends n/a
    Ask 103
    Volume 1,623,717
    Avg. Volume (20D) 1,943,391.8
    Open 100.35
    Previous Close 99.30
    Day's Range 99.48 - 102.84
    52-Week Range 68.70 - 156.66
    Beta 1.40
    Ex-Dividend Date n/a

    About ILMN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ILMN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ILMN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Illumina Inc. is scheduled to release its earnings on Nov 3, 2025, after market closes.
    Analysts project revenue of ... Unlock content with Pro Subscription
    4 days ago
    +7.68%
    Illumina shares are trading higher. The company an... Unlock content with Pro Subscription
    1 week ago
    -2.35%
    Shares of medical technology stocks are trading lower after the US opened national security investigations into imports of medical equipment, industrial machinery and robotics.
    news image

    1 day ago · zacks.com

    ILMN Stock Set to Benefit From the Launch of New BioInsight Division

    Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.

    news image

    2 days ago · zacks.com

    Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker

    ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.

    news image

    5 days ago · zacks.com

    KMDA vs. ILMN: Which Stock Is the Better Value Option?

    Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better ban...

    news image

    1 week ago · zacks.com

    TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?

    Investors are showing growing interest in the rapidly expanding Precision Oncology market, which is expected to witness a compound annual growth rate (CAGR) of 8% between 2025 and 2030, according to G...

    news image

    1 week ago · forbes.com

    ILMN Stock vs. IQV Stock

    Amid increased competition from China's MGI Tech, Illumina's stock (NASDAQ: ILMN) has dropped by 11% in a week. MGI Tech's DNA sequencers are reportedly gaining market share, and despite a recent decl...

    news image

    1 week ago · zacks.com

    Here's Why Illumina (ILMN) is a Strong Momentum Stock

    Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

    news image

    3 weeks ago · zacks.com

    ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay

    The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.

    news image

    1 month ago · zacks.com

    Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

    Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

    news image

    1 month ago · seekingalpha.com

    mRNA Biotechs - Long-Term Value Risks Abound

    mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...

    news image

    1 month ago · prismmediawire.com

    BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

    Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem's financial team POMPANO BEACH, FL, August 14, 2...

    Add to Watchlist